Attached files

file filename
EX-32.1 - EXHIBIT 32.1 - Protara Therapeutics, Inc.exh_321.htm
EX-31.2 - EXHIBIT 31.2 - Protara Therapeutics, Inc.exh_312.htm
EX-31.1 - EXHIBIT 31.1 - Protara Therapeutics, Inc.exh_311.htm
EX-21.1 - EXHIBIT 21.1 - Protara Therapeutics, Inc.exh_211.htm
10-K - FORM 10-K - Protara Therapeutics, Inc.f10k_031318p.htm

Exhibit 23.1

 

 

 

Consent of Independent Registered Public Accounting Firm

 

 

 

We consent to the incorporation by reference in the Registration Statement (Form S-8 No. 333-222415) pertaining to the 2014 Equity Incentive Plan, the 2014 Employee Stock Purchase Plan, and the Amended and Restated 2006 Equity Incentive Plan of Proteon Therapeutics, Inc.; the Registration Statement (Form S-3 No. 333- 207965) of Proteon Therapeutics, Inc.; and the Registration Statement (Form S-3 No. 333- 219676) of Proteon Therapeutics, Inc. and in the related Prospectus of our report dated March 14, 2018, with respect to the consolidated financial statements of Proteon Therapeutics, Inc., included in this Annual Report (Form 10-K) for the year ended December 31, 2017.

 

 

 

/s/ Ernst & Young LLP

 

 

 

 

 

Boston, Massachusetts

March 14, 2018